

(19) World Intellectual Property  
Organization  
International Bureau



10/550711



(43) International Publication Date  
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number  
WO 2004/085582 A2

- (51) International Patent Classification<sup>7</sup>: C11C 3/00
- (21) International Application Number:  
PCT/JP2004/004282
- (22) International Filing Date: 26 March 2004 (26.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
2003-088631 27 March 2003 (27.03.2003) JP
- (71) Applicant (for all designated States except US): SUN-  
TORY LIMITED [JP/JP]; 1-40, Dojimahama 2-chome,  
Kita-ku, Osaka-shi, Osaka 5308203 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): AKIMOTO,  
Kengo [JP/JP]; 1-9-5-1006, Yamazaki, Shimamoto-cho,  
Mishima-gun, Osaka 6180001 (JP). FUKAMI, Harukazu  
[JP/JP]; 36, Shimadezaikecho, Kissyoin, Minami-ku, Ky-  
oto-shi, Kyoto 6018373 (JP). GODA, Toshinao [JP/JP];  
21-11, Shimizukawaharacho, Shizuoka-shi, Shizuoka  
4240857 (JP).
- (74) Agents: AOKI, Atsushi et al.; A. Aoki, Ishida & As-  
sociates, Toranomon 37 Mori Bldg., 5-1, Toranomon  
3-chome, Minato-ku, Tokyo 1058423 (JP).
- (84) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.
- (84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished  
upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING LIPID-IMPROVING AGENT

(57) Abstract: A lipid-improving agent containing a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of a triglyceride(s).

BEST AVAILABLE COPY

WO 2004/085582 A2

## DESCRIPTION

LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING  
LIPID-IMPROVING AGENT

5

## Industrial Field

The present invention relates to a novel lipid-improving agent containing a poly-unsaturated fatty acid and having a structured lipid comprising a poly-

10

unsaturated fatty acid.

## Background Art

Fat is an important nutrient the same as protein and saccharide and it is particularly useful as a high energy source. However, because fat is high in calories (9

15

kcal/g), it promotes obesity and is a cause for problems such as lifestyle-related illnesses. Actually, when hyperlipemia (hypercholesterolemia, hypertriglyceridemia) is found, a diet therapy is adopted as a first method of treatment and, when appropriate dietetic therapy and

20

movement therapy are applied, the condition often improves and may become normalized. However, since fat enhances appetite, people today often eat foods containing large amounts of fat, and in advanced countries, where food is plentiful, excess fat intake is

25

becoming a problem. Most often, hypertriglyceridemia is a result of over eating, insufficient movement, obesity and excessive consumption of alcohol, and therefore, there are many cases where hypertension and diabetes mellitus occur as

30

complications at the same time. Therefore, in many cases where there are multiple risk factors or where it is hard to improve daily lifestyle habits, in order to prevent the onset of ischemic heart diseases, a positive drug therapy is carried out.

35

With regard to drugs for hypertriglyceridemia, there are drugs of a fibrate type (in Japan, bezafibrate) (Bezato1 SR<sup>R</sup> and Bezalip<sup>R</sup>) and fenofibrate (Lipantil<sup>R</sup>) are

known as fibrate type drugs of the second generation.  
The main action of mechanism of the fibrate type drugs is  
mediated by activation of transcription factor  $\alpha$  of an  
intranuclear receptor type (PPAR $\alpha$ : peroxisome  
proliferator-activated receptor  $\alpha$ ).

Therefore,  $\beta$ -oxidation of fatty acid is promoted and  
production of hepatic triglyceride(s) lowers, and as a  
result, production of VLDL-TG is suppressed. In  
addition, activation of PPAR $\alpha$  enhances an LPL activity  
and catabolism of triglyceride(s)-rich lipoprotein is  
accelerated. Further, an increase in the production of  
apo A I and A II and suppression of production of apo C  
III are induced. In addition, it has been noted that  
drugs of a fibrate type act to suppress cholesterol  
synthesis in the liver, promote sensitivity to insulin  
and promote discharge of cholesterol in bile. As a  
result, drugs of a fibrate type lower a triglyceride(s)  
concentration in serum by 20-50% and increase HDL-  
cholesterol by 10-15%.

As to other drugs, preparations of nicotinic acid  
(niceritrol (Perycit<sup>R</sup>) and nicomol (Cholexamin<sup>R</sup>)) have  
been found to be useful for hypertriglyceridemia and  
hyperglycemia of a mixed type (accompanied by  
hypertriglyceridemia, hypercholesterolemia and hypo-HDL-  
cholesterolemia). The main action mechanism of drugs of  
a nicotine type is that hepatic triglyceride(s) is  
lowered by inhibition of fatty acid synthesis,  
suppression of mobilization of fatty acid to the liver  
and suppression of esterification of hepatic fatty acid.  
At present, drugs of a fibrate type are used as the first  
choice, but in drug therapy, side effects such as hepatic  
function disorder, renal function disorder and myopathy  
must be noted. In addition, most side effects of drugs  
are expressed within six months after initiation of  
administration, and therefore, it is important to watch

for the onset of side effects when the effectiveness of the drug is tested during the period of six months or, at least three to four months, after the administration is started or the dosage is increased. Accordingly, very careful attention is necessary during the administration of drugs, and it is not possible to administer such drugs for the purpose of prevention.

At present, as a preventive means, development of substitutes for fat/oil and non-absorbing fat/oil has been carried out, an example being sucrose fatty acid polyester (U. S. Patent No. 3,600,186). Since it is discharged without being absorbed *in vivo*, the amount of calories derived from fat/oil is 0 kcal/g. However, absorption of fat-soluble vitamins is inhibited, and essential fatty acids are not supplied, and therefore, it is unable to be used as a commonly-used fat/oil. Under the circumstances, diacylglyceride has been developed in recent years as a source for supplying essential fatty acids.

In diacylglyceride, fatty acids are bonded mostly to 1,3-positions of a triglyceride(s), and upon being absorbed, fatty acids are cut out by a pancreatic lipase which is specific to 1,3-positions and the resulting glyceride and fatty acids are absorbed from the intestine. However, they are not reconstructed to a triglyceride(s) in epidermal cells of the small intestine but are absorbed with the portal vein and carried to the liver directly. Accordingly, accumulation of fat is suppressed. (In the case of a triglyceride(s), 2-acylmonoglyceride and fatty acid are absorbed in the intestine, reconstructed to a triglyceride(s) in epidermal cells of the small intestine, incorporated with chylomicron, secreted into lymph and circulate through the peripheral tissues.)

However, none of the developed fat/oil substitutes have the effect of drugs to burn fat *in vivo* ( $\beta$ -oxidation) and the effect is limited as well. Although

inhibitors for pancreatic lipase to suppress absorption have been developed as well, their effect is also limited.

#### Disclosure of the Invention

5           Therefore, there has been a strong demand for a compound which exhibits a lipid-improving action, is excellent for application to food and has little side effect.

10           Accordingly, the present invention is intended to provide a lipid-improving agent and beverage/food having a lipid-improving action containing, as an active ingredient, a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s), or a triglyceride(s) where a poly-  
15           unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s), and to provide a method for producing the same.

20           More particularly, the object of the present invention is to provide a lipid-improving agent and beverage/food having a lipid-improving action or, to be more specific, which functions such that neutral fat (triglyceride(s)) and/or cholesterol in blood are/is lowered, DL-cholesterol in blood is increased, stored fat  
25           is burned (promotion of  $\beta$ -oxidation), edible fat is burned (promotion of  $\beta$ -oxidation), expression of hepatic PPAR $\alpha$  which is a transcription factor of an intranuclear receptor type and/or related gene (such as hepatic  $\beta$ -oxidation enzyme gene) is enhanced and expression of  
30           PPAR $\gamma$  of fat tissues and/or related gene is suppressed, the lipid-improving agent containing an active ingredient, at least one member selected from a triglyceride(s) where poly-unsaturated fatty acid of omega-6 type, omega-3 type or omega-9 type is bonded to  
35           2-position of the triglyceride(s) and a triglyceride(s)

where poly-unsaturated fatty acid of omega-6 type, omega-3 type or omega-9 type is bonded to 2-position and saturated and/or mono-unsaturated fatty acid having not less than 8 carbons are/is bonded to 1,3-positions of the triglyceride(s), and to provide a method for producing the same.

The present inventors carried out a screening of components which activate a transcription factor of an intranuclear receptor type (PPAR) participating in lipid metabolism, a mechanism of drugs of a fibrate type which are the first choice for treatment of hypertriglyceridemia. It has been known that, when fat/oil is ingested, it enhances expression of PPAR $\alpha$  mRNA and promotes absorption of fatty acid and vitamin A in epidermal cells of the small intestine, while in the liver, it enhances expression of PPAR $\alpha$  mRNA and promotes  $\beta$ -oxidation of fatty acid. It has been also known that, as the PPAR ligand, poly-unsaturated fatty acid is more effective than saturated fatty and mono-unsaturated fatty acid. Therefore, the present inventors concentrated on poly-unsaturated fatty acid as a safe natural component which activates PPAR.

When fat/oil is absorbed, fatty acids bonded to 1,3-positions are cut out by a pancreatic lipase specific to 1,3-positions, and therefore, intensive studies were conducted based on the assumption that a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 1,3-positions of the triglyceride(s) is an ideal triglyceride(s) structure. It was surprisingly found that a triglyceride(s) where poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s) and also a triglyceride(s) where poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s), have greater activating action on PPAR. Since the poly-unsaturated fatty acid

bonded to 2-position is not cut out by a 1,3-position-specific pancreatic lipase, it was assumed that PPAR is rarely activated, but the results of the inventors' studies were contrary to expectation, and found thus the present invention was arrived at.

Accordingly, the present invention is intended to provide a lipid-improving agent and beverage/food having a lipid-improving action which contains, as an active ingredient, a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s), or a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s), and also to provide a method for producing the same.

More particularly, the present invention is intended to provide a lipid-improving agent and beverage/food having a lipid-improving action or, to be more specific, which functions such that neutral fat (triglyceride(s)) and/or cholesterol in blood are/is lowered, HDL-cholesterol in blood is increased, stored fat is burned (promotion of  $\beta$ -oxidation), edible fat is burned (promotion of  $\beta$ -oxidation), expression of hepatic PPAR $\alpha$  which is a transcription factor of an intranuclear receptor type and/or related gene (such as hepatic  $\beta$ -oxidation enzyme gene) is enhanced and expression of PPAR $\gamma$  of fat tissues and/or related gene is suppressed, the lipid-improving agent containing, as an active ingredient, at least one member selected from a triglyceride(s) where poly-unsaturated fatty acid of omega-6 type, omega-3 type or omega-9 type is bonded to 2-position of the triglyceride(s) and a triglyceride(s) where poly-unsaturated fatty acid of omega-6 type, omega-3 type or omega-9 type is bonded to 2-position and saturated and/or mono-unsaturated fatty acid having not less than 8 carbons are/is bonded to 1,3-positions of the

triglyceride(s), and also to provide a method for producing the same.

The present invention is able to provide a lipid-improving agent and beverage/food having a lipid-improving action containing, as an active ingredient, a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s), or a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and a saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s), and also to provide a method for producing the same. The present invention is particularly useful for humans in modern society.

#### Brief Explanation of the Drawings

Fig. 1 shows the result of examining the influence of fat/oil where arachidonic acid was bonded to 2-position of a triglyceride(s) on rat jejunum PPAR and related gene expression. The results are expressed in terms of relative values (mean value  $\pm$  standard error,  $n = 5$ ) where 0% arachidonic acid food group was 1 after correction by the amount of internal standard gene 18SrRNA. a-c: Significant difference noted between different alphabets ( $p < 0.05$ , Tukey). AOX: Acyl CoA Oxidase, CRBP II: Cellular Retinol-Binding Protein, Type II, L-FABP: Liver-type Fatty Acid-Binding Protein, I-FABP: Small Intestine-type Fatty Acid-Binding Protein.

Fig. 2 shows the result of examining the influence of fat/oil where arachidonic acid was bonded to 2-position of a triglyceride(s) on rat liver PPAR and related gene expression. The results are expressed in terms of relative values (mean value  $\pm$  standard error,  $n = 5$ ) where 0% arachidonic acid food group was 1 after correction by the amount of internal standard gene 18SrRNA. a,b: Significant difference noted between different alphabets ( $p < 0.05$ , Tukey). L-FABP: Liver-type Fatty Acid Binding Protein, AOX: Acyl CoA Oxidase,



UCP-2: Decoupling Protein, FAS: Fatty Acid-Synthetase.

Fig. 3 shows the result of examining the influence of fat/oil where arachidonic acid was bonded to 2-position of a triglyceride(s) on rat epididymis PPAR and related gene expression. The results are expressed in terms of relative values (mean value  $\pm$  standard error,  $n = 5$ ) where 0% arachidonic acid food group was 1 after correction by the amount of internal standard gene 18SrRNA. a-c: Significant difference noted between different alphabets ( $p < 0.05$ , Tukey). ap2: Fat Cell-Specific Fatty Acid-Binding Protein, UCP-2: Decoupling Protein, AOX: Acyl CoA Oxidase, FAS: Fatty Acid-Synthetase.

Fig. 4 shows the result of examining the influence of structured lipid containing arachidonic acid on rat liver PPAR and related gene expression. The results are expressed in terms of relative values (mean value  $\pm$  standard error,  $n = 5$ ) where 0% arachidonic acid food group was 1 after correction by the amount of internal standard gene 18SrRNA. a-c: Significant difference noted between different alphabets ( $p < 0.05$ , Tukey). L-FABP: Liver-type Fatty Acid-Binding Protein, I-FABP: Small Intestine-type Fatty Acid-Binding Protein, UCP-2: Decoupling Protein.

Fig. 5 shows the result of examining the influence of structured lipid containing arachidonic acid on rat epididymis white fat tissue PPAR and related gene expression. The results are expressed in terms of relative values (mean value  $\pm$  standard error,  $n = 5$ ) where 0% arachidonic acid food group was 1 after correction by the amount of internal standard gene 18SrRNA. a,b: Significant difference noted between different alphabets ( $p < 0.05$ , Tukey).

Embodiments for Carrying Out the Invention

The present invention relates to a lipid-improving agent and beverage/food having a lipid-improving action

containing, as an active ingredient, a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s), or a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and a saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s), and also to providing a method for producing the same.

The compound of the present invention and a composition containing said compound are effective as beverage/food, health food, functional food, designated health food, food for babies, food for aged people, drugs, quasi-drug, etc. with a purpose of prevention and improvement, having a lipid-improving action, to be more specific, having such action that neutral fat (triglyceride(s)) and/or cholesterol are/is lowered, HDL-cholesterol in blood is increased, stored fat is burned (promotion of  $\beta$ -oxidation) and edible fat is burned ( $\beta$ -oxidation) and, in view of mechanisms, in lever, expression of PPAR $\alpha$  which is a transcription factor of an intranuclear receptor type and/or related gene (such as acyl CoA oxidase and other enzymes in an  $\beta$ -oxidation system and an uncoupling protein (such as UCP-2)) is enhanced and expression of fatty acid synthetase (FAS) gene is suppressed, and, in fat cells, expression of PPAR $\gamma$  and/or related gene (such as fat cell-specific fat bonding protein (aP2) and an uncoupling protein (UCP-2)) is suppressed, expression of acyl CoA oxidase and other enzymes in a  $\beta$ -oxidation system and/or an uncoupling protein (UCP-2) gene is enhanced and expression of fatty acid synthetase (FAS) gene is suppressed.

The compound of the present invention is able to utilize a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s) and also a triglyceride(s) where a poly-unsaturated fatty

acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s).

Specific examples of the poly-unsaturated fatty acid bonding to 2-position are an unsaturated fatty acid of an omega-6 type (such as 9,12-octadecadienoic acid (linoleic acid) 18:2 $\omega$ 6, 6,9,12-octadecatrienoic acid ( $\gamma$ -linolenic acid), 18:3 $\omega$ 6, 8,11,14-eicosatrienoic acid (dihomo- $\gamma$ -linolenic acid) 20:3 $\omega$ 6,5,8,11,14-eicosatrienoic acid (arachidonic acid), 20:4 $\omega$ 6, 7,10,13,16-docosatetraenoic acid 22:4 $\omega$ 6 or 4,7,10,13,16-docosapentaenoic acid 22:5 $\omega$ 6), an unsaturated fatty acid of an omega-3 type (such as 9,12,15-octadecatrienoic acid ( $\alpha$ -linoleic acid) 18:3 $\omega$ 3, 6,9,12,15-octadecatetraenoic acid (stearidonic acid) 18:4 $\omega$ 3, 11,14,17-eicosatrienoic acid (dihomo- $\alpha$ -linolenic acid) 20:3 $\omega$ 3, 8,11,14,17-eicosatetraenoic acid 20:4 $\omega$ 3, 5,8,11,14,17-eicosapentaenoic acid 20:5 $\omega$ 3, 7,10,13,16,19-docosapentaenoic acid 22:5 $\omega$ 3 or 4,7,10,13,16,19-docosahexaenoic acid 22:6 $\omega$ 3) and an unsaturated fatty acid of an omega-9 type (such as 6,9-octadecadienoic acid 18:2 $\omega$ 9, 8,11-eicosadienoic acid 20:2 $\omega$ 9 or 5,8,11-eicosatrienoic acid (mead acid) 20:3 $\omega$ 9), but they are non-limitative and anything may be used so far as it is a poly-unsaturated fatty acid having not less than 18 carbons and not less than 2 double bonds. Examples of the saturated fatty acid and/or mono-unsaturated acid bonding to 1,3-positions are octanoic acid (caprylic acid) 8:0, decanoic acid (capric acid) 10:0, dodecanoic acid (lauric acid) 12:0, tetradecanoic acid (myristic acid) 14:0, hexadecanoic acid (palmitic acid) 16:0, octadecanoic acid (stearic acid) 18:0, 9-octadecanoic acid (oleic acid) 18:1 $\omega$ 9, arachidic acid

20:0 and behenic acid 22:0 although they are non-limitative and anything may be used so far as it is a saturated fatty acid or a mono-unsaturated fatty acid having not less than 8 carbons. It goes without saying that the fatty acids bonding to 1- and 3-positions are same or used in a combined manner.

Specific compounds are the following triglycerides such as 1,3-dipalmitoyl-2-arachidonoyl glyceride (16:0-20:4 $\omega$ 6-16:0), 1,3-dipalmitoyl-2-5,8,11,14,17-eicosapentanoyl glyceride (16:0-20:5 $\omega$ 3-16:0), 1,3-dipalmitoyl-2-4,7,10,13,16,19-docosahehexanoyl glyceride (16:0-22:6 $\omega$ 3-16:0), 1,3-dipalmitoyl-2-dihomo- $\gamma$ -linolenoyl glyceride (16:0-20:3 $\omega$ 6-16:0), 1,3-dipalmitoyl-2-meadnoyl glyceride (16:0-20:3 $\omega$ 9-16:0), 1,3-dicapryloyl-2-arachidonoyl glyceride (8:0-20:4 $\omega$ 6-8:0), 1,3-dicapryloyl-2-5,8,11,14,17-eicosapentanoyl glyceride (8:0-20:5 $\omega$ 3-8:0), 1,3-dicapryloyl-2-4,7,10,13,16,19-docosahehexanoyl glyceride (8:0-22:6 $\omega$ 3-8:0), 1,3-dicapryloyl-2-dihomo- $\gamma$ -linolenoyl glyceride (8:0-20:3 $\omega$ 6-8:0), 1,3-dicapryloyl-2-meadnoyl glyceride (8:0-20:3 $\omega$ 9-8:0), 1,3-dioleoyl-2-arachidonoyl glyceride (18:1 $\omega$ 9-20:4 $\omega$ 6-18:1 $\omega$ 9), 1,3-dioleoyl-2-5,8,11,14,17-eicosapentanoyl glyceride (18:1 $\omega$ 9-20:5 $\omega$ 3-18:1 $\omega$ 9), 1,3-oleoyl-2-4,7,10,13,16,19-docosahehexanoyl glyceride (18:1 $\omega$ 9-22:6 $\omega$ 3-18:1 $\omega$ 9), 1,3-dioleoyl-2-dihomo- $\gamma$ -linolenoyl glyceride (18:1 $\omega$ 9-20:3 $\omega$ 6-18:1 $\omega$ 9) and/or 1,3-dioleoyl-2-meadnoyl glyceride (18:1 $\omega$ 9-20:3 $\omega$ 9-18:1 $\omega$ 9) although they are non-limitative but anything may be utilized so far as it is a triglyceride(s) where poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s) or a triglyceride(s) where highly saturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid

are/is bonded to 1,3-positions of the triglyceride(s).

One of the effective ingredient of the present invention is a triglyceride(s) where highly saturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) and may be prepared, for example, by the following means.

Thus, one of specific processes for the production of a triglyceride(s) where poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) is that lipase which acts only on ester bonds at 1,3-positions of a triglyceride(s) is made to act in the presence of fat/oil (triglyceride(s)) containing poly-unsaturated fatty acid as a constituting fatty acid and a saturated fatty acid and/or mono-unsaturated fatty acid.

The fat/oil (triglyceride(s)) used as a starting material is a triglyceride(s) containing poly-unsaturated fatty acid of an omega-6 type, a poly-unsaturated fatty acid of an omega-3 type and/or a poly-unsaturated fatty acid of an omega-3 type as a constituting fatty acid. When the rate of the poly-unsaturated fatty acid to the total fatty acid constituting the triglyceride(s) is high, the temperature for the enzymatic reaction is to be 30 to 50°C or, preferably, 40 to 50°C being higher than the usual enzymatic reaction temperature which is 20 to 30°C in order to prevent a lowering of reaction yield as a result of an increase of the unreacted fat/oil (a starting triglyceride(s) and a triglyceride(s) where one of fatty acids at 1,3-positions becomes saturated fatty acid and/or mono-unsaturated fatty acid).

Examples of the lipase which specifically acts on the ester bond of 1,3-positions of the triglyceride(s) are those which are produced by microorganism such as genus *Rhizopus*, genus *Rhizomucor* and genus *Aspergillus* and pancreatic lipase of swine. With regard to the lipase

as such, commercially available one may be used. Its examples are lipase of *Rhizopus delemar* (Talipase manufactured by Tanabe Seiyaku), lipase of *Rhizomucor miehei* (Ribozyme IM manufactured by Novo Nordisk) and  
5 lipase of *Aspergillus niger* (Lipase A manufactured by Amano Seiyaku) although they are non-limitative, and anything may be used so far as it is a lipase which is specific to 1,3-positions.

With regard to the form for use of the above lipase,  
10 it is desirable to use a lipase which is immobilized on an immobilizing carrier to impart a heat resistance to the enzyme because the reaction is carried out at a temperature of not lower than 30°C or, preferably, not lower than 40°C with a purpose of enhancing the reaction  
15 efficiency. With regard to the immobilizing carrier, an ion-exchange resin carrier which is a highly porous resin having a pore size of not smaller than about 100Å such as Dowex Marathon WBA (a trade name; Dow Chemical) may be exemplified.

20 One part of the immobilizing carrier is suspended in 0.5 to 20 part(s) by weight of an aqueous solution of lipase specific to 1,3-positions and 2 to 5 parts of cold acetone (e.g., -80°C) to the suspension are added thereto gradually with stirring whereupon a precipitate is  
25 formed. An immobilized enzyme can be prepared by drying the precipitate *in vacuo*.

In a simpler method, 0.05 to 0.4 part(s) of lipase specific to 1,3-positions to one part of an immobilizing carrier is/are dissolved in a minimum amount of water,  
30 the immobilizing carrier is mixed therewith with stirring and the mixture is dried *in vacuo* to prepare an immobilized enzyme. As a result of the operation as such, about 90% of lipase are carried on a carrier but the product as it is does not show transesterifying  
35 activity at all. Thus, when it is subjected to a pretreatment in a substrate (comprising starting fat/oil and medium-chain fatty acid) to which 1 to 10% (w/v) of

water is/are added or, preferably, in a substrate to which 1 to 3% of water is/are added, the immobilized enzyme can be most efficiently activated and can be used for the manufacture.

5           In some types of enzymes, amount of water to be added to the present reaction system is very important. Thus, when no water is contained, the transesterifying reaction hardly proceeds while, when the amount of water is much, hydrolysis takes place and recovery rate of the  
10           glyceride lowers (when hydrolysis takes place, diglyceride and monoglyceride are produced). However, when an immobilized enzyme which is activated by means of a pretreatment is used in that case, the amount of water to be added to the present reaction system is no longer  
15           important and, even in a system containing no water at all, the transesterifying reaction is able to carried out efficiently. It is also possible to omit the pretreatment when the type of the enzyme preparation is duly selected.

20           When the heat-resistant immobilized enzyme as such is used and enzymatic reaction temperature is raised, it is now possible to efficiently manufacture a triglyceride(s) where saturated fatty acid and/or mono-unsaturated fatty acid is bonded to 1,3-positions and a  
25           highly saturated fatty acid is bonded to 2-position without lowering the reactivity even in the case of a fat/oil (triglyceride(s)) containing a poly-unsaturated fatty acid having low reactivity to lipase which is specific to 1,3-positions.

30           The fat/oil (triglyceride(s)) used as a starting material is a triglyceride(s) containing poly-unsaturated fatty acid of an omega-6 type, poly-unsaturated fatty acid of an omega-3 type and/or poly-unsaturated fatty acid of an omega-3 type, as a constituting fatty acid and  
35           examples of the triglyceride(s) where poly-unsaturated fatty acid of an omega 6 type is a constituting fatty acid are evening primrose oil (9,12-octadecadienoic acid

(linoleic acid) and 6,9,12-octadecatrienoic acid ( $\gamma$ -linolenic acid)) and borage oil (9,12-octadecadienoic acid (linoleic acid) and 6,9,12-octadecatrienoic acid ( $\gamma$ -linolenic acid)). In addition, a process for an effective production of a triglyceride(s) where 5,8,11,14-eicosatetraenoic acid (arachidonic acid) and 8,11,14-eicosatrienoic acid (di-homo- $\gamma$ -linoleic acid) are constituting fatty acids has been developed by the present inventors (P86-0087; JP-A-5-91887) and such a fat/oil may be also used as a starting fat/oil for an enzymatic reaction.

In the case of a triglyceride(s) where a poly-unsaturated fatty acid of an omega-9 type is a constituting fatty acid, a process for an effective production of a triglyceride(s) where 6,9-octadecadienoic acid 18:3 $\omega$ 9, 8,11-eicosadienoic acid 20:2 $\omega$ 9 or 5,8,11-eicosatrienoic acid (mead acid) 20:3 $\omega$ 9 is a constituting fatty acid has been developed by the present inventors (JP-A-5-91888, 10-57085 and 5-91886) and such a fat/oil may be also used as a starting fat/oil for an enzymatic reaction.

In the case of a triglyceride(s) where a poly-unsaturated fatty acid of an omega-3 type is a constituting fatty acid, fish oil such as tuna, bonito, sardine, mackerel, Pacific saury, cod, cuttlefish and horse mackerel may be used as a starting fat/oil for the enzymatic reaction. In fish oil, total fatty acid bonding to a triglyceride(s) is not always a poly-unsaturated fatty acid of an omega-3 type but, in some cases, a poly-unsaturated fatty acid of an omega-6 type is bonded as a constituting fatty acid. Fat/oil which is extracted from krill and algae such as chlorella and spirulina may also be used as a starting fat/oil for the enzymatic reaction.

It is also possible to use fat/oil prepared by



incubation of a microorganism which has been known to produce a triglyceride(s) where 4,7,10,13,16,19-docosahexaenoic acid 22:6 $\omega$ 3 is a constituting fatty acid such as that belonging to genus *Crypthecodenium*, genus *Thraustochytrium*, genus *Schizochytrium*, genus *Ulkenia*,  
5 genus *Japonochytrium* or genus *Haliphthoros* as a starting fat/oil for the enzymatic reaction.

As a saturated fatty acid and/or a mono-unsubstituted fatty acid which are/is to be starting  
10 material(s), it is possible to use a saturated fatty acid and/or a mono-unsubstituted fatty acid extracted from vegetable fat/oil and a medium-chain fatty acid having 8 to 12 carbons as materials for the enzymatic reaction. In addition, the material may be subjected to the  
15 reaction as fatty acid, fatty acid salt, alcohol ester of fatty acid and/or triglyceride(s).

The active ingredient of the present invention is a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or  
20 mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) and it has been known that octanoic acid (caprylic acid) 8:0 and 9-octadecanoic acid (oleic acid) 18:1 $\omega$ 9 enhance the expression of PPAR gene and a triglyceride(s) whereby such fatty acids are  
25 bonded to 1,3-positions can be an effective lipid-improving agent.

A triglyceride(s) prepared by an enzymatic method is unable to give 100% triglyceride(s) having a lipid-improving action where a poly-unsaturated fatty acid is  
30 bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) but, from the gist of the invention, it is apparent that fat/oil (triglyceride(s)) containing not less than 5 mol%,  
35 preferably not less than 10 mol%, more preferably not less than 20 mol% and, most preferably, not less than 30

mol% of the said triglyceride(s) is also a triglyceride(s) having a lipid-improving action.

Incidentally, it is apparent that a process for the production of a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions is not limited to an enzymatic synthesis but any process including chemical synthesis is able to be used.

10 In a process for the production of a composition having a lipid-improving action, a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions may be compounded, either  
15 solely or jointly, with a food material which does not substantially contains a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions or, if contained, the  
20 amount is little. Here, the expression that the amount is little means that, even when a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions is contained in a material  
25 for beverage/food, when the food composition compounded therewith is ingested by human being, the amount is still below the ingesting amount of the poly-unsaturated fatty acid per day of the present invention which will be mentioned later.

30 The compound of the present invention is a triglyceride(s) and there is an unlimited possibility concerning its use. The compound may be used as a material for food, beverage, drug and quasi-drug and an additive thereto. There is no limitation at all for its  
35 purpose of use and amount of use.

Besides the general food, examples of the food composition are functional food, nutritional supplement,

prepared milk for premature babies, prepared milk for babies, food for babies, food for expectant and nursing mothers and food for aged people. Examples of the food containing fat/oil are natural food which inherently  
5 contains fat/oil such as meat, fish and nut; food to which fat/oil is added upon cooking such as soup; food for which fat/oil is used as a heating medium such as doughnut; fat/oil food such as butter; processed food to which fat/oil is added upon processing such as cookie;  
10 and food to which fat/oil is sprayed or applied upon finishing the process such as hard biscuit. It is also possible to add to agricultural food, fermented food, livestock food, sea food or beverage which does not contain fat/oil. In addition, the form of functional  
15 food, drug and quasi-drug may be acceptable and it may be in a processed form such as enteral nutrient, powder, granule, troche, oral liquid, suspension, emulsion and syrup.

In addition to the effective ingredient of the  
20 present invention, the composition of the present invention may contain various carriers and additives which are commonly used for beverage/food, drug or quasi-drug. It is particularly preferred to contain an antioxidant to prevent the oxidation of the effective  
25 ingredient of the present invention. Examples of the antioxidant are natural ones such as tocopherols, flavone derivatives, phyllostulcins, kojic acid, gallic acid derivatives, catechins, fukiic acid, gossypol, pyrazine derivatives, sesamol, guaiaol, guaiacic acid, p-coumalic  
30 acid, nor-dihydroguaiaretic acid, sterols, terpenes, nucleic acid bases, carotenoids and lignans and synthetic ones represented by ascorbic palmitate, ascorbic stearate, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), mono-tert-butylhydroquinone (TBHQ) and 4-  
35 hydroxymethyl-2,6-di-tert-butylphenol (HMBP). Examples of the tocopherols are  $\alpha$ -tocopherol,  $\beta$ -tocopherol,  $\gamma$ -

tocopherol,  $\delta$ -tocopherol,  $\epsilon$ -tocopherol,  $\xi$ -tocopherol,  $\eta$ -tocopherol and tocopherol ester (such as tocopherol acetate). Examples of the carotenoids are  $\beta$ -carotene, canthaxanthin and astaxanthin.

5        Besides the effective ingredient of the present invention, the composition of the present invention may contain a carrier such as various carriers, extender, diluent, filler, dispersing agent, excipient, binder solvent (such as water, ethanol and vegetable oil),  
10        dissolving aid, buffer, dissolving promoter, gelling agent, suspending agent, wheat flour, rice powder, starch, corn starch, polysaccharide, milk protein, collagen, rice oil and lecithin, and additive such as  
15        vitamin compound, sweetener, organic acid, coloring agent, perfume, moisture preventer, fiber, electrolyte, mineral, nutrient, antioxidant, preservative, aromatic agent, moisturizer and natural food extract and vegetable extract although they are non-limitative.

20        Although the compound of the present invention is in a form of a triglyceride(s), active substance is a poly-unsaturated fatty acid bonded to 2-position of a triglyceride(s) which is a ligand for the transcription factor of an intranuclear receptor type (PPAR). It has been reported that ingesting amount of arachidonic acid  
25        from food per day is 0.14 g in Kanto District and 0.19 to 0.20 g in Kansai District (*Shishitsu Eiyogaku*, 4, 73-82, 1995) and the corresponding amount or more may be a yardstick for the ingestion of arachidonic acid.

30        Therefore, the daily ingesting amount of a triglyceride(s) where arachidonic acid is bonded to 2-position of triglyceride(s) or a triglyceride(s) where arachidonic acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) for an  
35        adult (such as that having a body weight of 60 kg) in terms of the amount of arachidonic acid is 0.001 to 20 g,

preferably 0.01 to 10 g, more preferably 0.05 to 5 g or, most preferably, 0.1 to 2 g. It has been reported that the daily ingesting amounts of 5,8,11,14,17-eicosapentaenoic acid 20:5 $\omega$ 3, 7,10,13,16,19-

5 docosapentaenoic acid 22:5 $\omega$ 3 and 4,7,10,13,16,19-docosahexaenoic acid 22:6 $\omega$ 3 docosahexanoic acid are 0.15, 0.05 and 0.27-0.37, respectively in Kanto District and are 0.35, 0.12-0.14 and 0.69-0.82, respectively in Kansai District and the corresponding amount or more may  
10 be a yardstick for the ingestion of arachidonic acid.

When a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s), a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and  
15 saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) and fat/oil (triglyceride(s)) containing said triglyceride(s) are actually applied to beverage/food, an absolute amount of the poly-unsaturated fatty acid which is to be  
20 compounded with the food is also important.

However, the absolute amount to be compounded with beverage/food also varies depending upon the ingesting amount of the beverage/food to be compounded and, therefore, it is compounded in an amount of not less than  
25 0.003% by weight, preferably not less than 0.03% by weight or, more preferably, not less than 0.3% by weight in terms of the amount of poly-unsaturated fatty acid. In addition, when a triglyceride(s) where a arachidonic acid is bonded to 2-position of the triglyceride(s) or a  
30 triglyceride(s) where arachidonic acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) is compounded, it is used at an amount not less than 0.001% by weight, preferably not less than  
35 0.01% by weight or, more preferably, not less than 0.1% by weight.

When the composition of the present invention is used as a drug, it is manufactured by a method which is common in the field of pharmaceutical preparations such as a method mentioned in the Japanese Pharmacopoeia or a method similar thereto.

When the composition of the present invention is used as a drug, the compounding amount of the effective ingredient in the composition is not particularly limited so far as the object of the present invention is achieved but an appropriate compounding rate may be used.

When the composition of the present invention is used as a drug, it is preferred to administer in a form of unit dosage form and an oral administration is particularly preferred. Dose of the composition of the present invention may vary depending upon age, body weight, symptom, frequency of administration, etc. and it is recommended that, for example, a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s) or a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) is administered per day to an adult (about 60 kg) in an amount of usually about 0.001 to 20 g, preferably about 0.01 to 10 g, more preferably about 0.05 to 5 g or, most preferably, about 0.1 to 2 g in terms of amount of the poly-unsaturated fatty acid by dividing into one to three times a day.

#### Examples

The present invention will now be more specifically illustrated by way of the following Examples although the present invention is not limited to the following Examples.

Example 1. Process for the production of a triglyceride(s) where arachidonic acid is bonded to 2-position of the triglyceride(s)

*Mortierella alpine* was used as an arachidonic acid-

producing microorganism. A medium (6 kL) containing 1.8% of glucose, 3.1% of defatted soybean powder, 0.1% of soybean oil, 0.3% of  $\text{KH}_2\text{PO}_4$ , 0.1% of  $\text{Na}_2\text{SO}_4$ , 0.05% of  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$  and 0.05% of  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$  was prepared in a 10-kL culture vessel and the initial pH was adjusted to 6.0. The pre-cultured solution (30 L) was inoculated and subjected to an aeration culture with stirring for 8 days under the condition where temperature was 26°C, aeration was 360 m<sup>3</sup>/hour and inner pressure of vessel was 200 kPa. The stirring was adjusted so as to keep the dissolved oxygen concentration 10 to 15 ppm.

With regard to a glucose concentration, the concentration within a medium was made within a range of 1 to 2.5% until the fourth day by means of a flowing-down method and, after that, it was kept at 0.5 to 1% (% hereinabove means weight (w/v) %). After completion of the culture, cells containing a triglyceride(s) where arachidonic acid is a constituting fatty acid is recovered by filtration and drying and fat/oil was extracted from the resulting cells with hexane and subjected to purifying steps for edible fat/oil (degumming, deacidifying, deodorizing and decoloring) to give 150 kg of arachidonic acid-containing triglyceride(s) (where arachidonic acid was bonded to any position of the triglyceride(s)). The resulting fat/oil (triglyceride(s)) was made into a methyl ester and the resulting fatty acid methyl ester was analyzed by a gas chromatography whereupon the rate of arachidonic acid in the total fatty acid was 40.84%.

Incidentally, palmitic acid, stearic acid, oleic acid, linoleic acid,  $\gamma$ -linolenic acid and di-homo- $\gamma$ -linolenic acid were 11.63%, 7.45%, 7.73%, 9.14%, 2.23% and 3.27%, respectively. Incidentally, the rate of a poly-unsaturated fatty acid at 2-position of a triglyceride(s) by a conventional analysis was 91.5% while that of arachidonic acid was 64.7%. Further, the above arachidonic acid-containing fat/oil

(triglyceride(s)) was made into an ethyl ester and a fatty acid ethyl ester mixture containing 40% of ethyl arachidonate was subjected to a conventional high-performance liquid chromatography to separate and purity 99% ethyl arachidonate. The resulting ethyl arachidonate was subjected to a conventional saponification reaction to prepare free arachidonic acid.

Example 2. Chemical synthesis of a triglyceride(s) (XPX) where saturated fatty acid and/or mono-unsaturated fatty acid (X) are/is bonded to 1,3-positions and a poly-unsaturated fatty acid (P) is bonded to 2-position and a triglyceride(s) (PXX) where a poly-unsaturated fatty acid (P) is bonded to 1-position and saturated fatty acid and/or mono-unsaturated fatty acid (X) are/is bonded to 2,3-positions or a triglyceride(s) (XXP) where a poly-unsaturated fatty acid (P) is bonded to 3-position and saturated fatty acid and/or mono-unsaturated fatty acid (X) are/is bonded to 1,2-positions

Synthesis of 8A8 (1,3-dioctanoyl-2-arachidonoyl glyceride)

A dihydroxyacetone dimer (1 g, 0.55 mmol) was dissolved in 20 ml of methylene chloride, then 3.5 ml (2.2 mmol) of n-octanoic acid and 70 mg of dimethylaminobenzene were added thereto and, under cooling with ice, 4.6 g (1.2 mmol) of WS-DCC were added. After 2 hours, the mixture was concentrated and extracted with ethyl acetate and the extract was washed with water, 1N HCl and a saturated saline solution successively. After it was dried over anhydrous magnesium sulfate, it was concentrated *in vacuo* and the resulting residue was crystallized from cold hexane to give 3 g (8.7 mmol) of 1,3-dioctanoyloxyacetone (yield: 79%).

The octanoate (10.8 g, 31.5 mmol) was dissolved in 120 ml of THF, 8 ml of water were added, the mixture was strongly stirred with ice-cooling and 1.2 g (31.7 mmol) of sodium borohydride were added thereto little by little together with making the pH neutral with acetic acid.



After completion of the addition, water which was made slightly acidic with 1N HCl was added, the mixture was extracted with ethyl acetate and the extract was washed with water and a saturated saline solution, dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The resulting oily substance was dissolved in 100 ml of methylene chloride, then 300 mg of dimethylaminobenzene and 8 g (26.4 mmol) of arachidonic acid were added thereto and the mixture was cooled with ice. WS-DCC (6.5 g, 34.4 mol) was further added thereto followed by stirring for 1 hour.

The reaction solution was concentrated and extracted with ethyl acetate and the extract was successively washed with water, 1N HCl and a saturated saline solution. It was then dried over anhydrous magnesium sulfate and concentrated *in vacuo* and the resulting residue was subjected to a silica gel chromatography using hexane-ethyl acetate (9:1) to give 13.5 g (yield: 68%) of 8A8 which was an oily substance. PMR (CDCl<sub>3</sub>)  $\delta$ : 0.8-1.0 (9H, m), 1.2-1.4 (22H, m), 1.6-1.8 (6H, m), 2.0-2.2 (4H, m), 2.3-2.4 (6H, m), 2.7-2.9 (6H, m), 4.14 (2H, q), 4.29 (2H, q), 5.2-5.5 (9H, m).

Synthesis of 88A (1(3),2-dioctanoyl-3(1)-arachidonoyl glyceride)

(RS)-2,2-Dimethyl-1,3-dioxolane-4-methanol (5 g, 37.8 mmol) was dissolved in 50 ml of DMF and, under cooling with ice, 1.6 g (39.7 mmol) of a 60% dispersion of sodium hydride in oil were added little by little. After completion, the mixture was stirred for 10 minutes and 4.5 ml (37.8 mmol) of benzyl bromide were dropped thereinto. After that, the mixture was stirred for 5 hours. After completion of the reaction, water was added, the mixture was extracted with ethyl acetate and the extract was washed with water and a saturated saline solution. This was dried over anhydrous magnesium sulfate and concentrated *in vacuo* and the resulting oily substance was subjected to a silica gel chromatography

with hexane-ethyl acetate (9:1) to give 6.5 g (yield: 77%) of 1(3),2-isopropylidene-3(1)-benzyloxyglyceride which was an oily substance. This substance (5.6 g, 25.2 mmol) was dissolved in 30 ml of acetic acid, 30 ml of water were added and the mixture was made to react at 60°C for 1 hour.

After the reaction solution was concentrated *in vacuo*, the residue was extracted with ethyl acetate and the extract was washed with a saturated aqueous solution of sodium bicarbonate and a saturated saline solution. This was dried over anhydrous magnesium sulfate and concentrated *in vacuo* to give 3.9 g of an oily product (yield: 85%). This product (3.8 g, 20.9 mmol) was dissolved in 40 ml of methylene chloride, 6.9 ml (43.9 mmol) of n-octanoic acid and 150 mg of dimethylaminobenzene were added and, under cooling with ice, 8.7 g (46 mmol) of WS-DCC were added. After 2 hours, the mixture was concentrated and extracted with ethyl acetate and the extract was washed with water, 0.5N NaOH and a saline solution successively. This was dried over anhydrous magnesium sulfate and concentrated *in vacuo* to give 9.9 g of an oily product. This was dissolved in 100 ml THF-25 ml acetic acid, then 1.3 g of 10% palladium-carbon were added and a reaction was carried out through one night in the presence of hydrogen. After the catalyst was filtered off, the filtrate was concentrated *in vacuo* and extracted with ethyl acetate and the extract was washed with a saturated aqueous solution of sodium bicarbonate and a saturated saline solution.

After drying over anhydrous magnesium sulfate, it was concentrated *in vacuo* and the resulting residue was subjected to a silica gel chromatography with hexane-ethyl acetate (9:1) to give 6 g of a debenzylated product (yield: 83%). The debenzylated product (136 mg, 0.39 mmol) was dissolved in 3 ml of methylene chloride, 100 mg (0.33 mmol) of arachidonic acid and 3 mg of

dimethylaminobenzene were added and, under cooling with ice, 90 mg (0.48 mmol) of WS-DCC were added. After 2 hours, the mixture was concentrated, extracted with ethyl acetate and the extract was washed with water, 1N HCl and a saturated saline solution successively. After drying over anhydrous magnesium sulfate, it was concentrated in vacuo and the resulting residue was subjected to a silica gel chromatography with hexane-ethyl acetate (9:1) to give 180 mg of an oily product (yield: 74%).

PMR (CDCl<sub>3</sub>)  $\delta$ : 0.8-1.0 (9H, m), 1.2-1.4 (22H, m), 1.5-1.8 (6H, m), 2.0-2.2 (4H, m), 2.3-2.4 (6H, m), 2.7-2.9 (6H, m), 4.1-4.2 (2H, m), 4.28 (2H, q), 5.3-5.5 (9H, m).

PAP (1,3-dipalmitoyl-2-arachidonoyl glyceride), PPA (1(3),2-dipalmitoyl-3(1)-arachidonoyl glyceride) and 8P8 (1,3-dioctaoyl-2-arachidonoyl glyceride) were also able to be prepared by the same method as in the case of 8A8 and 88A.

Example 3. Production of triglyceride(s) containing not less than 5% of triglyceride(s) (8A8) where medium-chain fatty acid is bonded to 1,3-positions and arachidonic acid is bonded to 2-position

An ion-exchange resin carrier (Dowex Marathon WBA; Dow Chemical; Trade Mark) (100 g) was suspended in 80 ml of a 12.5% aqueous solution of *Rhizopus delemar* lipase (Talipase Powder; Tanabe Seiyaku) and dried in vacuo to give an immobilized lipase.

After that, a reaction was carried out using 80 g of the triglyceride(s) (TGA 40S) containing 40% by weight of arachidonic acid prepared in Example 1, 160 g of caprylic acid, 12 g of the above immobilized lipase and 4.8 ml water at 30°C for 48 hours with stirring (130 rpm). After completion of the reaction, the reaction solution was removed to give an activated immobilized lipase.

Then the immobilized lipase (*Rhizopus delemar* lipase; carrier: Dowex Marathon WBA, trade mark) (10 g)

was filled in a glass column (1.8 × 12.5 cm; volume: 31.8 ml) equipped with a jacket, a mixed fat/oil where TGA 40S prepared in Example 1 and caprylic acid were mixed in 1:2 was flown into the column at a predetermined flow rate (4 ml/hour) and a continuous reaction was carried out to give 400 g of a reacted fat/oil. In the meanwhile, temperature of the column was kept at 40 to 41°C. From the resulting reacted fat/oil, unreacted caprylic acid and free fatty acids were removed by means of a molecular distillation followed by subjecting to purifying steps for edible fat/oil (degumming, deacidifying, deodorizing and decoloring) to give a fat/oil (triglyceride(s)) containing 8A8.

When the rate of 8A8 in the 8A8-containing fat/oil (triglyceride(s)) prepared by gas chromatography and high-performance liquid chromatography was checked, it was 31.6% (Incidentally, the rates of 8P8, 8O8, 8L8, 8G8 and 8D8 were 0.6, 7.9, 15.1, 5.2 and 4.8%, respectively).

Fatty acids P, O, L, G and D bonding to 2-position of the triglyceride(s) were palmitic acid, oleic acid, linoleic acid, γ-linolenic acid and dihomo-γ-linolenic acid, respectively while 8P8 was 1,3-capryloyl-2-palmitoyl-glyceride, 8O8 was 1,3-capryloyl-2-oleoyl-glyceride, 8L8 was 1,3-caproloyl-2-linoleoyl-glyceride, 8G8 was 1,3-capryloyl-2-γ-linolenoyl-glyceride and 8D8 was 1,3-capryloyl-2-dihomo-γ-linolenonyl-glyceride). Incidentally, the resulting 8A8-containing fat/oil (triglyceride(s)) was subjected to a conventional high-performance liquid chromatography to separate and purify 96 mol% of 8A8.

Example 4. Adjustment of expression of lipid metabolism gene by fat/oil where arachidonic acid is bonded to 2-position of triglyceride(s)

Influence of fat/oil (arachidonic acid-containing fat/oil) where arachidonic acid is bonded to 2-position of a triglyceride(s) prepared in Example 1 on expression

of gene related to lipid metabolism was tested using rats. Male rats of SD strain of 6 weeks age were divided into four groups. The arachidonic acid-containing fat/oil prepared in Example 1 was appropriately  
5 compounded with beef tallow, olive oil and corn oil to prepare four kinds of fat/oil as shown in Table 1 (0% AA, 14.6% AA, 26.8% AA and 37.7% AA) where arachidonic acid content was different and the experimental food shown in Table 2 (0% AA, 1% AA, 2.5% AA and 5% AA) was given for  
10 two weeks. The present experimental food was prepared in such a manner that the rate of arachidonic acid in the experimental food was made 0, 1, 2.5 and 5% while the rate of main fatty acids other than arachidonic acid in the experimental food was nearly the same (Table 3).

15 Ingestion of the food was conducted by a pair-feeding and body weight was measured every day. The experimental food was prepared using agar so that the daily ingested energy became same among each of the experimental food groups. After two weeks from ingestion  
20 of the experimental food, rats were killed by decapitation, the collected jejunum was perfused with a physiological saline solution which was treated with ice-cooled diethyl pyrocarbonate to remove the content therein, water was removed therefrom and then its weight  
25 was measured. With regard to liver and epididymis white fat tissues, weight of the whole tissues was measured. Further, according to a method of Chomezynski, et al., total RNA was extracted and prepared from each 100 mg of central jejunum, liver and epididymis white fat tissue  
30 and used for the measurement of expression of gene. In addition, blood upon killing by decapitation was collected and triglyceride(s) concentration and total cholesterol concentration in a serum fraction were quantified using a measuring kit (Triglyceride(s) E-Test  
35 Wako and Total Cholesterol E-Test Wako being used, respectively).

Total RNA (10  $\mu$ g or 30  $\mu$ g) extracted from each

tissue was subjected to an electrophoresis using 1% agarose gel containing 2.2M of formaldehyde gel and transferred to a nylon membrane (Hybond N+; Amersham) by 20 × SSC buffer for one night. The membrane to which the total RNA was transferred was pre-hybridized at 42°C for 2 hours using an Ultrahyb hybridization solution (Ambion) and then subjected to hybridization at 42°C for not shorter than 16 hours using each cDNA probe labeled with <sup>32</sup>P by a random primer method.

After completion of the hybridization, the membrane was incubated using a washing solution I (2 × SSPE, 0.5% SDS) at 42°C for 10 minutes (twice), then incubated using a washing solution III (0.1 × SSPE, 0.5% SDS) at 42°C for 15 minutes (once) and the membrane was washed. The surface of the washed membrane was exposed to light to an imaging plate (Fuji Photo Film) for 1 to 2 days and intensity of signal of mRNA on the membrane was analyzed by a bioimage analyzer BAS 200 (Fuji Photo Film).

Each of the measured results was expressed in terms of mean value ± standard error, the resulting data were tested by a dispersion analysis and the result where significance difference was noted thereby was subjected to a multigroup test according to Tukey. That where the ratio of risk was not more than 5% was considered to be significant.

Table 1. Fatty Acid Compositions of Four Kinds of Fat/Oil Having Different Arachidonic Acid Contents

Fat/Oil	0% AA	14.6% AA	26.8% AA	37.7% AA
Beef tallow	52.0	34.7	19.4	0
Olive oil	0	2.9	4.3	10.6
Arachidonic acid-containing fa/oil	0	32.9	60.2	84.8
Corn oil	48.0	29.4	16.1	4.5
Total (g)	100.0	100.0	100.0	100.0
Myristic acid (14:0)	1.0	0.8	0.6	0.4
Palmitic acid (16:0)	15.4	13.9	12.6	10.7
Palmitoleic acid (16:1)	1.6	1.1	0.7	0.1
Stearic acid (18:0)	11.8	10.2	8.7	6.4
Oleic acid (18:1 $\omega$ 9)	37.0	28.1	20.1	14.7
Linoleic acid (18:2 $\omega$ 2)	26.0	18.8	13.9	9.8
$\alpha$ -Linolenic acid (18:3 $\omega$ 3)	1.1	0.7	0.4	0.2
$\gamma$ -Linolenic acid (18:3 $\omega$ 6)	0	0.1	0.2	0.3
DGLA (20:3 $\omega$ 6)	0	1.1	2.0	2.8
Arachidic acid (20:0)	0.2	1.1	1.9	2.6
Arachidonic acid (10:4 $\omega$ 6)	0	14.6	26.8	37.7
Others	5.8	9.2	12.1	14.3

DGLA: Di-homo- $\gamma$ -linolenic acid

DGLA: Di-homo- $\gamma$ -linolenic acid

5 Table 2. Component Compositions of Experimental Food

g/kg	0% AA	1% AA	2.5% AA	5% AA
Casein (Vitamin-free)	159	159	159	159
$\beta$ -Corn starch	479	439	383	295
0% AA Mixed fat/oil	50			
14.6% AA Mixed fat/oil		68		
26.8% AA Mixed fat/oil			93	
37.7% AA Mixed fat/oil				132
Minerals AIN-76	28	28	28	28
Vitamins AIN-76	8	8	8	8
DL-Methionine	2	2	2	2
Choline bitartrate	2	2	2	2
2% Agar	272	294	325	374

Table 3. Rate of Each Fatty Acid in Experimental Food (%)

	0% AA	1% AA	2.5% AA	5% AA
Myristic acid (14:0)	0	0.1	0.1	0
Palmitic acid (16:0)	0.8	0.9	1.2	1.4
Palmitoleic acid (16:1)	0.1	0.1	0.1	0
Stearic acid (18:0)	0.6	0.7	0.8	0.8
Oleic acid (18:1 $\omega$ 9)	1.9	1.9	1.9	1.9
Linoleic acid (18:2 $\omega$ 2)	1.3	1.3	1.3	1.3
$\alpha$ -Linolenic acid (18:3 $\omega$ 3)	0.1	0	0	0
$\gamma$ -Linolenic acid (18:3 $\omega$ 6)	0	0	0	0
DGLA (20:3 $\omega$ 6)	0	0.1	0.2	0.4
Arachidic acid (20:0)	0	0.1	0.2	0.3
Arachidonic acid (20:4 $\omega$ 6)	0	1.0	2.5	5.0
Others	0.3	0.6	1.1	1.9

DGLA: Di-homo- $\gamma$ -linolenic acid

DGLA: Di-homo- $\gamma$ -linolenic acid

- 5           Influence on tissue weight and serum lipid concentration after 2 weeks of ingestion of the experimental food is shown in Table 4. Weight of epididymis white fat tissues corresponding to inner visceral fat lowered corresponding to the arachidonic acid amount in the experimental food and, in a 5% AA experimental food, the decrease was significant. In addition, serum total cholesterol and triglyceride(s) concentrations significantly lowered corresponding to the arachidonic acid amount in the experimental food.
- 10
- 15       Lowering of the serum triglyceride(s) concentration was particularly significant and, in a group of 1% AA food, the lowering was 53% of a group of 0% AA food. Incidentally, under the condition of the present experimental raising loaded with arachidonic acid, no abnormal symptom such as inflammation caused by
- 20       production of excessive eiconoside was observed and it was confirmed that there was no problem at all so far as arachidonic acid is ingested as a constituting fatty acid for a triglyceride(s).



Table 4. Influence of Ingestion of Experimental Food on Body Weight Increase, Relative Tissue Weight and Serum Lipid Concentration in Rats

	0% AA	1% AA	2.5% AA	5% AA
Body weight increase (g/14 days)	91 ± 3	90 ± 7	89 ± 10	80 ± 5
Ingested amount (g/day)	27.5 ± 0.3	26.2 ± 0.7	27.4 ± 0.6	26.2 ± 0.6
Liver weight (g/100 g body weight)	4.0 ± 0.1	3.7 ± 0.3	4.0 ± 0.4	4.2 ± 0.1
Epididymis fat tissue weight (g/100 g body weight)	1.7 ± 0.1 <sup>a</sup>	1.4 ± 0.1 <sup>ab</sup>	1.4 ± 0.1 <sup>ab</sup>	1.2 ± 0.1 <sup>b</sup>
Serum triglyceride(s) concn (μmol/dl)	242 ± 19.7 <sup>a</sup>	128 ± 20.3 <sup>b</sup>	112 ± 12.8 <sup>b</sup>	87.0 ± 12.3 <sup>b</sup>
Serum total cholesterol concn (μmol/dl)	257 ± 6.25 <sup>a</sup>	239 ± 19.2 <sup>a</sup>	209 ± 16.5 <sup>b</sup>	144 ± 14.2 <sup>b</sup>

a,b: significant difference noted between different alphabets (p < 0.05)

In jejunum of rats, expressed amount of PPARα mRNA increased to an extent of about 1.5- to 1.7-fold in the groups of 2.5% and 5% AA food (Fig. 1). On the other hand, expressed amount of PPARδ mRNA in jejunum lowered depending upon the arachidonic acid content in the feed. In addition, expressed amount of jejunum CRBP II, L-FABP, I-FABP and AOX mRNA which are target genes for PPARα increased depending upon the ingested arachidonic acid content. Since retinol which is absorbed in jejunum is a hydrophobic nutrient, most of it is present in cytoplasm as being bonded to a combined protein. A cellular retinol-bonded protein type II (CRBP II) plays an important role in intracellular transportation and esterification of retinol is.

Therefore, it is now apparent that arachidonic acid efficiently mediates absorption and metabolism of fat-soluble vitamins by way of an increase of expressed amount of PPAR α mRNA and an increase of expressed amount of jejunum CRBP II mRNA. From the above result,

it has become clear that arachidonic acid ingested into small intestine functions as a ligand mainly for PPAR $\alpha$  either directly or as a precursor for eicosanoids.

5 In liver, expressed amount of PPAR $\alpha$  mRNA increased in a group of 1% AA food and a group of 2.5% AA food while, in a 5% AA food group, it decreased. However, expressed amounts of L-FABP, AOX and UCP-2 mRNA which are PPAR $\alpha$  target genes increased depending upon the amounts of arachidonic acid and showed the highest value in a 5%  
10 AA food group. Although that is different from a variation pattern of PPAR $\alpha$  mRNA, it can be said as a result that arachidonic acid activates the PPAR $\alpha$  and adjusts the gene expression in a safe and effective manner until its amount reaches 2.5%. From the above, it  
15 has become clear that suppression of fatty acid synthesis system (not by way of PPAR) and promotion of fatty acid decomposition system accompanied by an increase of expressed amount of PPAR $\alpha$  (by way of PPAR) are controlled in a genetic level and concentration of  
20 triglyceride(s) in blood is lowered.

In epididymis white fat tissues, expressed amounts of PPAR $\alpha$  and PPAR $\delta$  mRNA significantly lowered depending upon the amount of arachidonic acid. Further, expressed amount of fat cell-specific fatty acid bonded protein  
25 (aP2) mRNA also lowered depending upon the concentration. It has been known that PPAR $\delta$  participates in differentiation and induction of fat cells and promotes the fat accumulation in white fat tissues, and a decrease of epididymis fat tissue weight by ingestion of  
30 arachidonic acid (Table 4) suppresses numbers and size of white fat cells or, in other words, differentiation and aging of fat cells by way of decrease of expressed amount of PPAR $\delta$  mRNA. On the other hand, expressed amount of white fat tissue AOX mRNA increased as a result of

increase of amount of arachidonic acid and, therefore, promotion of fatty acid decomposition system was also observed.

5     Example 5. Adjustment of lipid metabolism gene expression by arachidonic acid-containing structured lipid

          Influence of the structured lipid where arachidonic acid chemically synthesized in Example 2 as a constituting fatty acid on expression of lipid metabolism-related gene was investigated using rats. The effects were compared among PPP where palmitic acid (P) is bonded to 1,2,3-positions of a triglyceride(s), a mixture of same amounts of PPA where palmitic acid is bonded to 2-position and arachidonic acid is bonded to 3-position of a triglyceride(s) with APP where palmitic acid is bonded to 2,3(1)-positions and arachidonic acid is bonded to 1(3)-position of a triglyceride(s) (in chemical synthesis, it is a mixture of same amounts of PPA and APP and, hereinafter, such as mixture in the same amounts will be referred to as PPA for the sake of convenience) and PAP where palmitic acid is bonded to 1,3-positions and arachidonic acid is bonded to 2-position of a triglyceride(s) which are examples of the structured lipid.

25           Male rats of SD strain of 5 weeks age were divided into four groups each comprising five rats, acclimatized for one week with a standard solid feed and ingested for two weeks with an experimental food (10% PPA and 10% PAP; Table 5) compounded with 10% of arachidonic acid-containing structured lipid (PPA or PAP). In the control group, an experimental food (10% PPP) compounded with 10% of PPP was used. In ingestion of the food, a pair-feeding was conducted and body weight was measured every day. The experimental food was prepared using agar so  
35     that the daily ingested energy became same among each of the experimental food groups.

          After two weeks from ingestion of the experimental

food, rats were killed by decapitation and, according to the same method as in Example 4, each tissue was collected and total RNA was extracted and then analysis of gene expression was carried out by a northern blotting.

Table 5. Component Compositions of Experimental Food

	Low-Fat	10% PPP	10% PPA	10% PAP
	g/kg feed			
Casein (Vitamin-free)	157	157	157	157
$\beta$ -Corn starch	526	301	301	301
Corn oil	23	24	24	24
PPP		100		
PPA			100	
PAP				100
Minerals AIN-G93	28	28	28	28
Vitamins AIN-93	8	8	8	8
DL-Methionine	2.4	2.4	2.4	2.4
Choline bitartrate	1.6	1.6	1.6	1.6
2% Agar	253	378	378	378

Each of the feeds was added with 0.25 g/kg diet of  $\alpha$ -tocopherol.

Influence of on tissue weight and serum lipid concentration after 2 weeks from ingestion of the experimental food is shown in Table 6. Serum triglyceride(s) concentration was significantly high in a group of 10% PPP food while, in the groups of 10% PPA and 10% PAP food, there was no significant difference from a low-fat food group. Although the same 10% fat/oil were added to a low-fat food (2.4% corn oil), serum triglyceride(s) significantly lowered showing the similar value as the low-fat food group when one of fatty acids binding to a triglyceride(s) was substituted with arachidonic acid. With regard to serum total cholesterol concentration, low values were noted in the groups of 10% PPA and 10% PAP foods as compared with a 10% PPP food group.

Table 6. Influence of Ingestion of Experimental Food on Body Weight Increase, Relative Tissue Weight and Serum Lipid Concentration in Rats

	Low-fat	10% PPP	10% PPA	10% PAP
Body weight increase (g/14 days)	71 ± 5 <sup>ab</sup>	61 ± 5 <sup>a</sup>	80 ± 4 <sup>b</sup>	67 ± 5 <sup>ab</sup>
Liver weight (g/100 g body weight)	4.4 ± 0.3	4.3 ± 0.3	4.2 ± 0.1	3.4 ± 0.8
Serum triglyceride(s) concn (μmol/dl)	191 ± 32.3 <sup>a</sup>	316 ± 64.3 <sup>b</sup>	173 ± 6.6 <sup>b</sup>	174 ± 7.5 <sup>b</sup>
Serum total cholesterol concn (μmol/dl)	235 ± 7.8 <sup>a</sup>	201 ± 9.2 <sup>a</sup>	150 ± 16.6 <sup>b</sup>	178 ± 15.3 <sup>ab</sup>

a,b: significant difference observed between different alphabets (p < 0.05)

5                   Influence of structured lipid on expression of target gene of PPAR of jejunum is shown (Fig. 4). From PPA, each one molecule of palmitic acid and arachidonic acid is dissociated and absorbed by the action of

10                  pancreatic lipase specific to 1,3-positions and arachidonic acid having a particularly strong PPAR ligand activity acts as a PPAR $\alpha$  ligand in small intestine and, therefore, expressed amount of target gene of PPAR

15                  increased in a group of 10% PPA food as compared with a PPP food group which is a control group. On the other hand, when it is considered that two molecules of dissociated palmitic acid and one molecule of 2-arachidonoyl monoglyceride (2-AG) are produced from PAP

20                  and are incorporated into epidermal cells of small intestine, it is assumed that, since palmitic acid has a weak action as a PPAR ligand, there will be almost no influence on the expression of target gene of PPAR in a group of 10% PAP food as compared with a group of PPP food which is a control group. However, the result was

25                  entirely the contrary being similar to or even more than the group of 10% PPA food.

                  Expressed amount of PPAR $\alpha$  mRNA of liver significantly increased in a group of PAP food (Fig. 5).

In jejunum, a significant action of a monoglyceride (2-AG) where arachidonic acid is bonded by the action of lipase specific to 1,3-positions was found and it was proved that the same effect was available in liver as well. Two molecules of palmitic acid and one molecule of 2-AG incorporated into epidermal cells of small intestine are reconstructed to a triglyceride(s) (in that case, although there is a possibility of bonding of other inherent fatty acids existing in the epidermal cells of the small intestine to 1,3-positions, arachidonic acid bonded to 2-position is retained), incorporated into chylomicron, transferred to peripheral tissues together with secretion of lymph and blood flow and finally incorporated into liver.

The result that PAP significantly increased the expressed amount of PPAR $\alpha$  in the liver shows that a triglyceride(s) structure where arachidonic acid is bonded to 2-position is retained to an extent of liver and achieves the function and the significance of bonding of arachidonic acid, i.e. a poly-unsaturated fatty acid, at 2-position has been proved. As compared with a low-fat food where fat/oil load is 2.4%, the structured lipid load of 10% (total fat/oil load being 12.4%) of PPP, PPA and PAP foods is not an extreme fat load and, therefore, although there is no difference between PPA and PAP in view of serum triglyceride(s) concentration and serum total cholesterol concentration, there is a clear difference in a level of expression of gene whereby it is apparent that, in an extreme lipid load, PAP (a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position) significantly lowers the serum lipid concentration.

Example 6. Serum lipid lowering action by structured lipid containing arachidonic acid

Influence of arachidonic acid chemically synthesized in Example 2 on serum lipid lowering action of the constituting fatty acid was investigated in a high-fat

foods. The effects were compared using structured lipids which were PPP, PPA and PAP being the same as in Example 5 as well as 8P8 where caprylic acid (8) is bonded to 1,3-positions and palmitic acid is bonded to 2-position of a triglyceride(s), a mixture of the same amounts of 88A where caprylic acid is bonded to 1,2-positions and arachidonic acid is bonded to 3-position of a triglyceride(s) with A88 where caprylic acid is bonded to 2,3-positions and arachidonic acid is bonded to 1-position of a triglyceride(s) (a mixture of same amounts of 88A with A88 is prepared in chemical synthesis; such a mixture of same amounts of them will be referred to as 88A hereinafter for the sake of convenience) and 8A8 where caprylic acid is bonded to 1,3-positions and arachidonic acid is bonded to 2-position of a triglyceride(s).

Male rats of SD strain of 5 weeks age were divided into eight groups each comprising five rats, acclimatized for one week with a standard solid feed and ingested for two weeks with the experimental food as shown in Table 7 and Table 8 (normal, high-TG, 7.5% PPP, 7.5% PAP, 7.5% PPA, 7.5% 8P8, 7.5% 8A8 and 7.5% 88A). Incidentally, the condition for a high-fat food was that the rate of fat/oil in the feed was made 20%, beef tallow abundant in saturated fatty acid was used as a base and 2% of corn oil were compounded to avoid the deficiency of essential fatty acids. In the control group, an experimental food (high-TG food, 20% fat/oil food) compounded with 18% of 8P8 (20% as a result of addition of 2% of corn oil) was used.

After two weeks from ingestion of the experimental food, rats were killed by decapitation and triglyceride(s) concentration and total cholesterol concentration in a serum fraction were quantified using a measuring kit (Triglyceride(s) E-Test Wako and Total Cholesterol E-Test Wako being used, respectively).

Table 7. Component Composition of Experimental Food

	Normal Food	High-TG Food (20% Fat)	High-TG Food (7.5% PPP)	High-TG Food (7.5% PAP)	High-TG Food (7.5% PPA)
	g/kg Feed				
Casein	200	200	200	200	200
DL-Methionine	3	3	3	3	3
Corn starch	150	150	150	150	150
Sucrose	500	350	350	350	350
Cellulose powder	50	50	50	50	50
Minerals AIN-76	35	35	35	35	35
Vitamins AIN-76	10	10	10	10	10
Choline bitartrate	2	2	2	2	2
Corn oil	20	20	20	20	20
Beef tallow	30	180	105	105	105
PPP			75		
PAP				75	
PPA					76
8P8					
8A8					
88A					

Table 8. Component Composition of Experimental Food

	High-TG Food (7.5% 8P8)	High-TG Food (7.5% 8A8)	High-TG Food (7.5% 88A)
	g/kg Feed		
Casein	200	200	200
DL-Methionine	3	3	3
Corn starch	150	150	150
Sucrose	350	350	350
Cellulose powder	50	50	50
Minerals AIN-76	35	35	35
Vitamins AIN-76	10	10	10
Choline bitartrate	2	2	2
Corn oil	20	20	20
Beef tallow	105	105	105
PPP			
PAP			
PPA			
8P8	75		
8A8		75	
88A			75

Influences after two weeks from ingestion of the experimental food on tissue weight and serum lipid concentration are shown in Table 9. Serum



triglyceride(s) concentration showed significantly high values in a high-triglyceride(s) food group. Although a 7.5% PPP food group which is a control group showed no change at all, a 7.5% PPA food group and a 7.5% PAP food group significantly lowered the serum triglyceride(s). With regard to the effects of PAP and PPA, a 7.5% PAP food group showed significantly low values. Similar result was also shown in structured lipid groups (7.5% 8P8, 7.5% 8A8 and 7.5% 88A) where caprylic acid is a constituting fatty acid. It has been confirmed that, when a medium-chain fatty is used as a constituting fatty acid, an effect of lowering the serum triglyceride(s) is able to be significantly enhanced. Similar result was also found concerning serum total cholesterol concentration.

It has been known that not only arachidonic acid but also poly-unsaturated fatty acids adjust the serum triglyceride(s) concentration and the serum cholesterol concentration by way of PPAR and it is apparent that, like in the case of bonding of arachidonic acid to 2-position, the similar effect is achieved in the structured lipid to which a poly-unsaturated fatty acid is bonded to 2-position.

Table 9. Influence of Ingestion of Experimental Food on Serum Lipid Concentration

	Normal Food	High-TG Food (20% Fat)	High-TG Food (7.5% PPP)	High-TG Food (7.5% PAP)
Serum Triglyceride(s) Conc'n ( $\mu\text{mol/dl}$ )	45.0 $\pm$ 5.9 <sup>a</sup>	103.0 $\pm$ 5.6 <sup>b</sup>	109.2 $\pm$ 6.8 <sup>b</sup>	80.4 $\pm$ 3.9 <sup>a</sup>
Serum Total Cholesterol Conc'n ( $\mu\text{mol/dl}$ )	80.2 $\pm$ 2.8 <sup>a</sup>	102.4 $\pm$ 4.9 <sup>b</sup>	104.3 $\pm$ 5.9 <sup>b</sup>	91.7 $\pm$ 3.3 <sup>a</sup>
	High-TG Food (7.5% PPA)	High-TG Food (7.5% 8P8)	High-TG Food (7.5% 8A8)	High-TG Food (7.5% 88A)
Serum Triglyceride(s) Conc'n ( $\mu\text{mol/dl}$ )	93.1 $\pm$ 1.3 <sup>a</sup>	101.8 $\pm$ 5.3 <sup>b</sup>	63.3 $\pm$ 4.1 <sup>a</sup>	83.1 $\pm$ 3.6 <sup>a</sup>
Serum Total Cholesterol Conc'n ( $\mu\text{mol/dl}$ )	92.4 $\pm$ 4.9 <sup>a</sup>	99.7 $\pm$ 4.2 <sup>b</sup>	85.6 $\pm$ 2.5 <sup>b</sup>	92.9 $\pm$ 2.9 <sup>a</sup>

a,b: significant difference observed between different alphabets (p < 0.05)

5        Example 7. Example for preparation of capsules compounded with fat/oil (triglyceride(s)) where arachidonic acid is bonded to 2-position of triglyceride(s)

10        Gelatin (100 parts by weight) and 35 parts by weight of glyceride for food additive were dissolved in water at 50 to 60°C to prepare a gelatin film having a viscosity of 2,000 cp. Then the fat/oil (triglyceride(s)) prepared in Example 1 where arachidonic acid is bonded to 2-position of triglyceride(s) was mixed with 0.05% by weight of vitamin E oil to prepare a content 1. Vitamin E oil (0.05% by weight) was compounded with the fat (triglyceride(s)) prepared in Example 3 where 32 mol% of 8A8 were contained to prepare a content 2. Capsule formation and drying were carried out by a conventional method using those contents 1 and 2 to prepare soft capsules each containing 200 mg of the content.

15

20

Example 8. Serum lipid improving action in humans after ingestion of fat (triglyceride(s)) where arachidonic acid is bonded to 2-position of triglyceride(s)

5 The test of the present invention to humans was carried out with careful consideration following the spirit of the Helsinki Declaration. Firstly, explanation for consent in joining the test was conducted and six capsules of the fat/oil where arachidonic acid was bonded to 2-position of triglyceride(s) prepared in Example 7 (80 mg/capsule in terms of arachidonic acid) were ingested for one months to eight people who consented. Before and after ingestion of the capsules, blood was collected and blood biochemical markers were analyzed.

10 Result of the measurement is shown in Table 10. The serum triglyceride(s) concentration significantly lowered by ingestion of the capsules. Although the serum cholesterol concentration significantly increased, that was not due to an increase of concentration of LDL-cholesterol which was the bad cholesterol but due to a significant increase of concentration of HDL-cholesterol which was the good cholesterol. From the above, it has been confirmed that serum lipid is improved by the fat/oil where arachidonic acid is bonded to 2-position of a triglyceride(s).

Table 10. Result of Physical Examination Before and After Ingestion of Capsules of Fat/Oil where Arachidonic Acid is Binding to 2-Position of Triglyceride(s)

	Before	After
Height (cm)	169.8 ± 5.9	169.8 ± 5.9
Body Weight (kg)	65.1 ± 6.5	65.0 ± 5.9
Neutral Fat/Oil (Triglyceride(s))	99.4 ± 28.0 <sup>a</sup>	74.1 ± 17.5 <sup>b</sup>
Total Cholesterol	175.9 ± 17.6 <sup>a</sup>	184.9 ± 18.6 <sup>b</sup>
HDL-Cholesterol	58.5 ± 10.2 <sup>a</sup>	63.1 ± 10.0 <sup>b</sup>
LDL-Cholesterol	106.9 ± 19.4	108.3 ± 17.6

a,b: significant difference observed between different alphabets (p < 0.05)

Example 9. Serum triglyceride(s) lowering action in humans after ingestion of capsules of edible fat/oil containing 8A8

Explanation for the consent of joining the test was conducted as same as in Example 8 and three capsules of the edible fat/oil containing 8A8 prepared in Example 7 (72 mg/capsule in terms of arachidonic acid) were ingested for one months to eight people who consented. Before and after ingestion of the capsules, serum triglyceride(s) concentration was analyzed whereupon it showed significant lowering from  $162 \pm 29.3$  to  $83.3 \pm 14.9$ .

Example 10. Use for Fat Transfusion Preparation

The fat/oil (triglyceride(s)) containing 96% of 8A8 prepared in Example 3 (400 g), 48 g of pure egg yolk lecithin, 20 g of oleic acid, 100 g of glyceride and 40 ml of 0.1N sodium hydroxide were mixed and homogenized and then distilled water for injection was added thereto to make 4 liters. This was emulsified using a high-pressure spraying emulsifier to prepare a lipid emulsion. Each 200 ml of the lipid emulsion was disposed into a bag made of plastic and sterilized with a high-pressure steam at  $121^{\circ}\text{C}$  for 20 minutes to give a fat transfusion preparation.

Example 11. Use for Juice

$\beta$ -Cyclodextrin (2 g) was added to 20 ml of a 20% aqueous solution of ethanol, 100 mg of the fat/oil where arachidonic acid was bonded to 2-position of a triglyceride(s) (compounded with 0.05% of vitamin E) prepared in Example 1 were added thereto and the mixture was incubated at  $50^{\circ}\text{C}$  for 2 hours. After cooling to room temperature (for about 1 hour), incubation was further conducted at  $4^{\circ}\text{C}$  for 10 hours together with stirring. The resulting precipitate was recovered by centrifugal separation, washed with n-hexane and freeze-dried to give 1.8 g of an inclusion compound of cyclodextrin containing

the fat/oil where arachidonic acid was bonded to 2-position of a triglyceride(s). The powder (1 g) was homogeneously mixed with 10 liters of juice to prepare a juice which contained the fat/oil where arachidonic acid  
5 was bonded to 2-position of a triglyceride(s).

CLAIMS

1. A lipid-improving agent containing a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s).

5 2. The lipid-improving agent according to claim 1, wherein the agent contains a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s).

10 3. The lipid-improving agent according to claim 1 or 2, wherein the poly-unsaturated fatty acid is an omega-6 type unsaturated fatty acid.

15 4. The lipid-improving agent according to any of claims 1 to 3, wherein the omega-6 unsaturated fatty acid is arachidonic acid.

20 5. The lipid-improving agent according to any of claims 1 to 4, wherein the agent contains a fat/oil prepared by incubation of a microorganism which is able to produce a triglyceride(s) where arachidonic acid is bonded to 2-position of the triglyceride(s).

6. The lipid-improving agent according to any of claims 1 to 5, wherein the microorganism mentioned in claim 5 is a microorganism belonging to genus *Mortierella*.

25 7. The lipid-improving agent according to claim 1 or 2, wherein the poly-unsaturated fatty acid is an omega-3 type unsaturated fatty acid.

30 8. The lipid-improving agent according to claim 1 or 2, wherein the poly-unsaturated fatty acid is an omega-9 type unsaturated fatty acid.

35 9. The lipid-improving agent according to any of claims 1 to 3, wherein the omega-6 type poly-unsaturated fatty acid is 9,12-octadecadienoic acid (linoleic acid) 18:2 $\omega$ 6, 6,9,12-octadecatrienoic acid ( $\gamma$ -linolenic acid) 18:3 $\omega$ 6, 8,11,14-eicosatrienoic acid (dihomo- $\gamma$ -linolenic acid) 20:3 $\omega$ 6, 5,8,11,14-eicosatrienoic acid (arachidonic

acid) 20:4 $\omega$ 6, 7,10,13,16-docosatetraenoic acid 22:4 $\omega$ 6 or 4,7,10,13,16-docosapentaenoic acid 22:5 $\omega$ 6.

10. The lipid-improving agent according to claim 1, 2 or 7, wherein the omega-3 type unsaturated fatty acid  
5 is 9,12,15-octadecatrienoic acid ( $\alpha$ -linolenic acid) 18:3 $\omega$ 3, 6,9,12,15-octadecatetraenoic acid (stearidonic acid) 18:4 $\omega$ 3, 11,14,17-eicosatrienoic acid (dihomo- $\alpha$ -linolenic acid) 20:3 $\omega$ 3, 8,11,14,17-eicosatetraenoic acid 20:4 $\omega$ 3, 5,8,11,14,17-eicosapentaenoic acid 20:5 $\omega$ 3,  
10 7,10,13,16,19-docosapentaenoic acid 22:5 $\omega$ 3 or 4,7,10,13,16,19-docosahexaenoic acid 22:6 $\omega$ 3.

11. The lipid-improving agent according to claim 1, 2 or 8, wherein the omega-9 type unsaturated fatty acid  
15 is 6,9-octadecadienoic acid 18:2 $\omega$ 9, 8,11-eicosadienoic acid 20:2 $\omega$ 9 or 5,8,11-eicosatrienoic acid (mead acid) 20:3 $\omega$ 9.

12. The lipid-improving agent according to claim 2, wherein the saturated fatty acid or the mono-unsaturated fatty acid is selected from octanoic acid (caprylic acid)  
20 8:0, decanoic acid (capric acid) 10:0, dodecanoic acid (lauric acid) 12:0, tetradecanoic acid (myristic acid) 14:0, hexadecanoic acid (palmitic acid) 16:0, octadecanoic acid (stearic acid) 18:0, 9-octadecanoic acid (oleic acid) 18:1 $\omega$ 9, arachidic acid 20:0 and  
25 behenic acid 22:0 and the fatty acids bonding to 1- and 3-positions are same or combined.

13. The lipid-improving agent according to any of claims 1 to 12, wherein the triglyceride(s) is selected from 1,3-dipalmitoyl-2-arachidonoyl glyceride (16:0-  
30 20:4 $\omega$ 6-16:0), 1,3-dipalmitoyl-2-5,8,11,14,17-eicosapentanoyl glyceride (16:0-20:5 $\omega$ 3-16:0), 1,3-dipalmitoyl-2-4,7,10,13,16,19-docosahexanoyl glyceride (16:0-22:6 $\omega$ 3-16:0), 1,3-dipalmitoyl-2-dihomo- $\gamma$ -linolenoyl

glyceride (16:0-20:3 $\omega$ 6-16:0), 1,3-dipalmitoyl-2-meadnoyl  
glyceride (16:0-20:3 $\omega$ 9-16:0), 1,3-dicapryloyl-2-  
arachidonoyl glyceride (8:0-20:4 $\omega$ 6-8:0), 1,3-  
dicapryloyl-2-5,8,11,14,17-eicosapentanoyl glyceride  
5 (8:0-20:5 $\omega$ 3-8:0), 1,3-dicapryloyl-2-4,7,10,13,16,19-  
docosahehexanoyl glyceride (8:0-22:6 $\omega$ 3-8:0), 1,3-  
dicapryloyl-2-dihomo- $\gamma$ -linolenoyl glyceride (8:0-20:3 $\omega$ 6-  
8:0), 1,3-dicapryloyl-2-meadnoyl glyceride (8:0-20:3 $\omega$ 9-  
8:0), 1,3-dioleoyl-2-arachidonoyl glyceride (18:1 $\omega$ 9-  
10 20:4 $\omega$ 6-18:1 $\omega$ 9), 1,3-dioleoyl-2-5,8,11,14,17-  
eicosapentanoyl glyceride (18:1 $\omega$ 9-20:5 $\omega$ 3-18:1 $\omega$ 9), 1,3-  
oleoyl-2-4,7,10,13,16,19-docosahehexanoyl glyceride  
(18:1 $\omega$ 9-22:6 $\omega$ 3-18:1 $\omega$ 9), 1,3-dioleoyl-2-dihomo- $\gamma$ -  
linolenoyl glyceride (18:1 $\omega$ 9-20:3 $\omega$ 6-18:1 $\omega$ 9) and/or 1,3-  
15 dioleoyl-2-meadnoyl glyceride (18:1 $\omega$ 9-20:3 $\omega$ 9-18:1 $\omega$ 9).

14. The lipid-improving agent according to claim 1,  
wherein it lowers neutral fat (triglyceride(s)) and/or  
cholesterol in blood.

15. The lipid-improving agent according to claim 1,  
20 wherein it increases HDL-cholesterol in blood.

16. The lipid-improving agent according to claim 1,  
wherein it burns stored fat.

17. The lipid-improving agent according to claim 1,  
wherein it burns edible fat.

25 18. The lipid-improving agent according to claim 1,  
wherein it is mediated by a transcription factor of an  
intranuclear receptor type (PPAR).

19. The lipid-improving agent according to claim 1  
or 14, wherein the PPAR is PPAR $\alpha$  of liver and enhances  
30 PPAR $\alpha$  and/or related gene expression.

20. The lipid-improving agent according to claim 1,  
18 or 19, wherein the related gene is hepatic  $\beta$ -oxidation  
gene.



21. The lipid-improving agent according to claim 1, 18 or 19, wherein the PPAR is a PPAR $\gamma$  of fat tissue and suppresses PPAR $\gamma$  and/or related gene expression.

5 22. A composition having a lipid-improving action which contains a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s).

10 23. The composition having a lipid-improving action according to claim 22, wherein the composition contains a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s).

15 24. The composition according to claim 22 or 23, wherein the poly-unsaturated fatty acid is an omega-6 type unsaturated fatty acid.

25. The composition according to claim 24, wherein the omega-6 unsaturated fatty acid is arachidonic acid.

20 26. The composition according to any of claims 22 to 25, wherein the composition contains fat/oil prepared by incubation of a microorganism which is able to produce a triglyceride(s) where arachidonic acid is bonded to 2-position of the triglyceride(s).

25 27. The composition according to any of claims 22 to 26, wherein the microorganism mentioned in claim 26 is a microorganism belonging to genus *Mortierella*.

28. The composition according to claim 22 or 23, wherein the poly-unsaturated fatty acid is an omega-3 type unsaturated fatty acid.

30 29. The composition according to claim 22 or 23, wherein the poly-unsaturated fatty acid is an omega-9 type unsaturated fatty acid.

35 30. The composition according to any of claims 22 to 24, wherein the omega-6 type unsaturated fatty acid is 9,12-octadecadienoic acid (linoleic acid) 18:2 $\omega$ 6, 6,9,12-octadecatrienoic acid ( $\gamma$ -linolenic acid) 18:3 $\omega$ 6,

8,11,14-eicosatrienoic acid (dihomo- $\gamma$ -linolenic acid)  
20:3 $\omega$ 6, 5,8,11,14-eicosatrienoic acid (arachidonic acid)  
20:4 $\omega$ 6, 7,10,13,16-docosatetraenoic acid 22:4 $\omega$ 6 or  
4,7,10,13,16-docosapentaenoic acid 22:5 $\omega$ 6.

5           31. The composition according to 23, wherein the  
omega-3 type unsaturated fatty acid is 9,12,15-  
octadecatrienoic acid ( $\alpha$ -linolenic acid) 18:3 $\omega$ 3,  
6,9,12,15-octadecatetraenoic acid (stearidonic acid)  
18:4 $\omega$ 3, 11,14,17-eicosatrienoic acid (dihomo- $\alpha$ -linolenic  
10 acid) 20:3 $\omega$ 3, 8,11,14,17-eicosatetraenoic acid 20:4 $\omega$ 3,  
5,8,11,14,17-eicosapentaenoic acid 20:5 $\omega$ 3,  
7,10,13,16,19-docosapentaenoic acid 22:5 $\omega$ 3 or  
4,7,10,13,16,19-docosahexaenoic acid 22:6 $\omega$ 3.

15           32. The composition according to claim 29, wherein  
the omega-9 type unsaturated fatty acid is 6,9-  
octadecadienoic acid 18:2 $\omega$ 9, 8,11-eicosadienoic acid  
20:2 $\omega$ 9 or 5,8,11-eicosatrienoic acid (mead acid) 20:3 $\omega$ 9.

20           33. The composition according to claim 23, wherein  
the saturated fatty acid or the mono-unsaturated fatty  
acid is selected from octanoic acid (caprylic acid) 8:0,  
decanoic acid (capric acid) 10:0, dodecanoic acid (lauric  
acid) 12:0, tetradecanoic acid (myristic acid) 14:0,  
hexadecanoic acid (palmitic acid) 16:0, octadecanoic acid  
(stearic acid) 18:0, 9-octadecanoic acid (oleic acid)  
25 18:1 $\omega$ 9, arachidic acid 20:0 and behenic acid 22:0 and  
the fatty acids bonding to 1- and 3-positions are same or  
combined.

30           34. The composition according to any of claims 22  
to 33, wherein the triglyceride(s) is selected from 1,3-  
dipalmitoyl-2-arachidonoyl glyceride (16:0-20:4 $\omega$ 6-16:0),  
1,3-dipalmitoyl-2-5,8,11,14,17-eicosapentanoyl glyceride  
(16:0-20:5 $\omega$ 3-16:0), 1,3-dipalmitoyl-2-4,7,10,13,16,19-  
docosahexanoyl glyceride (16:0-22:6 $\omega$ 3-16:0), 1,3-

dipalmitoyl-2-dihomo- $\gamma$ -linolenoyl glyceride (16:0-20:3 $\omega$ 6-16:0), 1,3-dipalmitoyl-2-meadnoyl glyceride (16:0-20:3 $\omega$ 9-16:0), 1,3-dicapryloyl-2-arachidonoyl glyceride (8:0-20:4 $\omega$ 6-8:0), 1,3-dicapryloyl-2-5,8,11,14,17-eicosapentanoyl glyceride (8:0-20:5 $\omega$ 3-8:0), 1,3-dicapryloyl-2-4,7,10,13,16,19-docosahexanoyl glyceride (8:0-22:6 $\omega$ 3-8:0), 1,3-dicapryloyl-2-dihomo- $\gamma$ -linolenoyl glyceride (8:0-20:3 $\omega$ 6-8:0), 1,3-dicapryloyl-2-meadnoyl glyceride (8:0-20:3 $\omega$ 9-8:0), 1,3-dioleoyl-2-arachidonoyl glyceride (18:1 $\omega$ 9-20:4 $\omega$ 6-18:1 $\omega$ 9), 1,3-dioleoyl-2-5,8,11,14,17-eicosapentanoyl glyceride (18:1 $\omega$ 9-20:5 $\omega$ 3-18:1 $\omega$ 9), 1,3-oleoyl-2-4,7,10,13,16,19-docosahexanoyl glyceride (18:1 $\omega$ 9-22:6 $\omega$ 3-18:1 $\omega$ 9), 1,3-dioleoyl-2-dihomo- $\gamma$ -linolenoyl glyceride (18:1 $\omega$ 9-20:3 $\omega$ 6-18:1 $\omega$ 9) and/or 1,3-dioleoyl-2-meadnoyl glyceride (18:1 $\omega$ 9-20:3 $\omega$ 9-18:1 $\omega$ 9).

35. The composition according to claim 22, wherein it lower neutral fat (triglyceride(s)) and/or cholesterol in blood.

36. The composition according to claim 22, wherein it increases HDL-cholesterol in blood.

37. The composition according to claim 22, wherein it burns stored fat.

38. The composition according to claim 22, wherein it burns edible fat.

39. The composition according to claim 22, wherein it is mediated by a transcription factor of an intranuclear receptor type (PPAR).

40. The composition according to claim 22 or 38, wherein the PPAR is PPAR $\alpha$  of liver and enhances PPAR $\alpha$  and/or related gene expression.

41. The composition according to claim 22, 23 or 39, wherein the related gene is hepatic  $\beta$ -oxidation gene.

42. The composition according to claim 22 or 38, wherein the PPAR is a PPAR $\gamma$  of fat tissue and suppresses PPAR $\gamma$  and/or related gene expression.

5 43. The composition according to any of claims 1 to 41, wherein it is a food composition or a pharmaceutical composition.

44. A food composition which contains a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s) in such a  
10 manner that a daily ingested amount of the triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of the triglyceride(s) for an adult per day in made 0.001 to 20 g in terms of the amount of the poly-unsaturated fatty acid.

15 45. The food composition according to claim 43, wherein the composition contains a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) in  
20 such a manner that a daily ingested amount of the triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) for an adult per day in  
25 made 0.001 to 20 g in terms of the amount of the poly-unsaturated fatty acid.

46. The composition according to claim 43 or 44, wherein the composition contains a triglyceride(s) where arachidonic acid is bonded to 2-position and saturated  
30 fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions of the triglyceride(s) in such a manner that a daily ingested amount of the triglyceride(s) where arachidonic acid is bonded to 2-position and saturated fatty acid and/or mono-unsaturated  
35 fatty acid are/is bonded to 1,3-positions of the triglyceride(s) for an adult per day in made 0.001 to 20

g in terms of the amount of arachidonic acid.

47. The food composition according to claim 43 or 45, wherein the composition contains not less than 0.001% by weight of a composition in which the triglyceride(s) is selected from 1,3-dipalmitoyl-2-arachidonoyl glyceride (16:0-20:4 $\omega$ 6-16:0), 1,3-dipalmitoyl-2-5,8,11,14,17-eicosapentanoyl glyceride (16:0-20:5 $\omega$ 3-16:0), 1,3-dipalmitoyl-2-4,7,10,13,16,19-docosahexanoyl glyceride (16:0-22:6 $\omega$ 3-16:0), 1,3-dipalmitoyl-2-dihomo- $\gamma$ -linolenoyl glyceride (16:0-20:3 $\omega$ 6-16:0), 1,3-dipalmitoyl-2-meadnoyl glyceride (16:0-20:3 $\omega$ 9-16:0), 1,3-dicapryloyl-2-arachidonoyl glyceride (8:0-20:4 $\omega$ 6-8:0), 1,3-dicapryloyl-2-5,8,11,14,17-eicosapentanoyl glyceride (8:0-20:5 $\omega$ 3-8:0), 1,3-dicapryloyl-2-4,7,10,13,16,19-docosahexanoyl glyceride (8:0-22:6 $\omega$ 3-8:0), 1,3-dicapryloyl-2-dihomo- $\gamma$ -linolenoyl glyceride (8:0-20:3 $\omega$ 6-8:0), 1,3-dicapryloyl-2-meadnoyl glyceride (8:0-20:3 $\omega$ 9-8:0), 1,3-dioleoyl-2-arachidonoyl glyceride (18:1 $\omega$ 9-20:4 $\omega$ 6-18:1 $\omega$ 9), 1,3-dioleoyl-2-5,8,11,14,17-eicosapentanoyl glyceride (18:1 $\omega$ 9-20:5 $\omega$ 3-18:1 $\omega$ 9), 1,3-oleoyl-2-4,7,10,13,16,19-docosahexanoyl glyceride (18:1 $\omega$ 9-22:6 $\omega$ 3-18:1 $\omega$ 9), 1,3-dioleoyl-2-dihomo- $\gamma$ -linolenoyl glyceride (18:1 $\omega$ 9-20:3 $\omega$ 6-18:1 $\omega$ 9) and/or 1,3-dioleoyl-2-meadnoyl glyceride (18:1 $\omega$ 9-20:3 $\omega$ 9-18:1 $\omega$ 9).

48. The composition according to any of claims 43 to 46, wherein the food composition is functional food, nutritional supplement, designated health food or food for aged people.

49. A process for the production of a composition having a lipid-improving action which is a process for the production of a food composition, characterized in that, a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position and saturated fatty acid

and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions is compounded, either solely or jointly, with a food material which does not substantially contains a triglyceride(s) where a poly-unsaturated fatty acid is  
5 bonded to 2-position and saturated fatty acid and/or mono-unsaturated fatty acid are/is bonded to 1,3-positions or, if contained, the amount is little.

Fig.1




Fig. 2






Fig.3






Fig. 4



5/5

Fig.5



(19) World Intellectual Property  
Organization  
International Bureau



10/550711



(43) International Publication Date  
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number  
**WO 2004/085582 A3**

(51) International Patent Classification<sup>7</sup>: **A23D 9/00**,  
A23L 1/30

(21) International Application Number:  
PCT/JP2004/004282

(22) International Filing Date: 26 March 2004 (26.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2003-088631 27 March 2003 (27.03.2003) JP

(71) Applicant (for all designated States except US): **SUN-  
TORY LIMITED** [JP/JP]; 1-40, Dojimahama 2-chome,  
Kita-ku, Osaka-shi, Osaka 5308203 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AKIMOTO**,  
**Kengo** [JP/JP]; 1-9-5-1006, Yamazaki, Shimamoto-cho,  
Mishima-gun, Osaka 6180001 (JP). **FUKAMI**, **Harukazu**  
[JP/JP]; 36, Shimadezaikecho, Kissyoin, Minami-ku, Ky-  
oto-shi, Kyoto 6018373 (JP). **GODA**, **Toshinao** [JP/JP];  
21-11, Shimizukawaharacho, Shizuoka-shi, Shizuoka  
4240857 (JP).

(74) Agents: **AOKI**, Atsushi et al.; A. Aoki, Ishida & As-  
sociates, Toranomon 37 Mori Bldg., 5-1, Toranomon  
3-chome, Minato-ku, Tokyo 1058423 (JP).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).


#### Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
2 December 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING LIPID-IMPROVING AGENT



(57) Abstract: A lipid-improving agent containing a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of a triglyceride(s).

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A23D9/00 A23L1/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23D A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, COMPENDEX, BIOSIS, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 200301 Derwent Publications Ltd., London, GB; Class B04, AN 2003-003195 XP002293655 & JP 2002 180082 A (MARUHA CORP) 26 June 2002 (2002-06-26) abstract	1-49
X	WO 02/06505 A (HATA KAZUHIKO ; YAMANE TSUNEO (JP); FURIHATA KIYOMI (JP); ROXANA IRIME) 24 January 2002 (2002-01-24) abstract	1-49
X	WO 03/004667 A (FUJIKAWA SHIGEAKI ; HIGASHIYAMA KENICHI (JP); AKIMOTO KENGO (JP); SUNT) 16 January 2003 (2003-01-16) abstract	1-49
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

24 August 2004

Date of mailing of the international search report

07/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Rooney, K

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AKIKO KAWASHIMA ET AL: "Enzymatic synthesis of high-purity structured lipids with caprylic acid at 1,3-positions and polyunsaturated fatty acid at 2-position" JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, AMERICAN OIL CHEMISTS' SOCIETY. CHAMPAIGN, US, vol. 78, no. 6, June 2001 (2001-06), pages 611-616, XP002957827 ISSN: 0003-021X abstract -----	1-49
X	NAMAL SENANAYAKE, S. P. J., AND SHAHIDI, F.: "Positional distribution of FA in TAG of enzymatically modified borage and evening primrose oils." LIPIDS, vol. 37, no. 8, 2002, pages 803-810, XP008034095 USCHAMPAIGN, IL the whole document -----	1-49
X	JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY., vol. 45, 1999, pages 411-421, XP002293654 JPUNIVERSITY OF TOKYO PRESS, TOKYO abstract -----	1-49

## Information on patent family members

International Application No

T/JP2004/004282

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 2002180082	A	26-06-2002	NONE	
WO 0206505	A	24-01-2002	JP 2002027995 A	29-01-2002
			AU 6790001 A	30-01-2002
			CN 1441848 T	10-09-2003
			EP 1300470 A1	09-04-2003
			WO 0206505 A1	24-01-2002
			US 2004033571 A1	19-02-2004
WO 03004667	A	16-01-2003	CA 2452401 A1	16-01-2003
			EP 1411129 A1	21-04-2004
			WO 03004667 A1	16-01-2003

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**